Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.

[1]  A. Tefferi,et al.  A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions , 2010, European journal of haematology.

[2]  K. Sotlar,et al.  Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD) , 2010, The Journal of pathology.

[3]  A. Tefferi,et al.  Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature , 2010, Current opinion in hematology.

[4]  A. Órfão,et al.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. , 2009, The Journal of allergy and clinical immunology.

[5]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[6]  E. Iannitto,et al.  Advanced mast cell disease: an Italian Hematological Multicenter experience , 2008, International journal of hematology.

[7]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[8]  R. Moriggl,et al.  Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens1 , 2008, The Journal of Immunology.

[9]  L. Pagano,et al.  Mast cell leukemia: a report of ten cases , 2008, Annals of Hematology.

[10]  A. Feller,et al.  Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material , 2007, Diagnostic pathology.

[11]  A. Órfão,et al.  Recent advances in the understanding of mastocytosis: the role of KIT mutations * , 2007, British journal of haematology.

[12]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[13]  K. Elenitoba-Johnson,et al.  Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR , 2007, Journal of Clinical Pathology.

[14]  S. Verstovsek,et al.  Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease , 2007, Leukemia.

[15]  A. Dobrovic,et al.  Sensitive detection of KIT D816V in patients with mastocytosis. , 2006, Clinical chemistry.

[16]  M. Lacouture,et al.  Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. , 2006, The Journal of molecular diagnostics : JMD.

[17]  A. Órfão,et al.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.

[18]  D. Steensma.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. , 2006, The Journal of molecular diagnostics : JMD.

[19]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[20]  G. Delsol,et al.  Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation , 2005, The Journal of experimental medicine.

[21]  M. Raffeld,et al.  Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. , 2004, The Journal of molecular diagnostics : JMD.

[22]  Cem Akin,et al.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. , 2004, Blood.

[23]  A. Órfão,et al.  Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA) , 2004, Cytometry. Part B, Clinical cytometry.

[24]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[25]  L. Ashman,et al.  Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. , 2003, Leukemia research.

[26]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.

[27]  U. Lass,et al.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. , 2003, The American journal of pathology.

[28]  Olivier Hermine,et al.  Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms , 2003, Oncogene.

[29]  M Roederer,et al.  Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. , 2001, Cytometry.

[30]  P. Valent,et al.  Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis , 2001, British journal of haematology.

[31]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[32]  D. Metcalfe,et al.  Clinical correlates of the presence of the asp816Val c‐kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis , 1998, Cancer.